Evogene (NASDAQ: EVGN) reported Q1 EPS of ($0.06), $0.26 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $334 thousand versus the consensus estimate of $3 million.

For earnings history and earnings-related data on Evogene (EVGN) click here.